Insider and Congress filings

Twist Bioscience Corporation (TWST)

Biotechnology, listed on NASDAQ.

25 insider transactions2 Congress tradeslast filed Nov 5, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ4 FY2026 · reported Nov 12, 2026

Twist Bioscience beat on EPS, and revenue beat by 2.5%.

-$0.32 a share against a -$0.39 consensus. Revenue $127M against $124M.

EPS

Reported-$0.32
Consensus-$0.39

Revenue

Reported$127M
Consensus$124M

Beat 3Miss 3

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Next report Feb 1, 2027. Consensus -$0.39 a share.

Every quarter

Money managersEach manager’s last 13F filing

2

of the 97 fund managers GetSignal tracks list Twist Bioscience among their largest positions. Cathie Wood held the most, $656.6M.

Every manager

Insider tradesForm 4 · 16 open-market filings shown

16 open-market sales, 4 of them under 10b5‑1 plans.

Sep 24, 2026Nov 3, 2026

SalesSales under a plan

4 of 16 under a plan

A median 2 business days from trade to filing. Form 4 is due within two.

Every filing
Companyfrom the company's filings and listing, as of Nov 15, 2026

About Twist Bioscience Corporation

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
Emily Marine Leproust
Employees
979
Listed since
Oct 31, 2018
Market value
$7.3B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$2.08
Dividend yield
-

www.twistbioscience.com

Earnings6 reported quarters · next on Feb 1, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q4 FY2026reported Nov 12, 2026-$0.32-$0.39$126.6M$123.5MEPS beatRevenue beat
Q3 FY2026reported Aug 3, 2026-$0.56-$0.51$118.4M$114.5MEPS miss, GAAPRevenue beat
Q2 FY2026reported May 4, 2026-$0.71-$0.49$110.7M$107.6MEPS miss, GAAPRevenue beat
Q1 FY2026reported Feb 2, 2026-$0.50-$0.48$103.7M$101.9MEPS miss, GAAPRevenue beat
Q4 FY2025reported Nov 14, 2025-$0.45-$0.50$99.0M$97.4MEPS beatRevenue beat
Q3 FY2025reported Aug 4, 2025-$0.47-$0.54$96.1M$97.4MEPS beatRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Earnings call briefs1 call

Earnings call briefs

Fiscal Q4 2026 call

Twist Bioscience sees potential for triple-digit AI order growth in fiscal 2027

CFO Adam Laponis said he expects fiscal 2027 gross margin to still expand, despite about $15 million a year of depreciation, or about 2 to 3 points of headwind.

Expected fiscal 2027 AI drug discovery revenue assumption
$100 million, from programs it can forecast with high confidence
Expected fiscal 2027 and fiscal 2028 capital expenditures
approximately $150 million for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements
Expected fiscal 2027 depreciation on capital spending of about $75 million
approximately $15 million a year

Read the full brief

Written by GetSignal with AI from each earnings call; every brief quotes the executives' own words. Key facts are what the company said on the call, not our forecast. Not investment advice.

Earnings call briefs from every company we cover

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on TWST, newest first
FirmRatingTargetActionDate
TD CowenBuy$137Target set
CanaccordBuyrated Oct 12, 2026$150Target set
JefferiesNot stated$125Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice. A rating with its own date under it is the firm's latest from the past 120 days, where the note stated none.

6 other firms rated TWST in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 16, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Jan 6, 2026

Executive pay

Emily M. Leproust, Ph.D.’s pay as CEO came to $13.8M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Emily M. Leproust, Ph.D.Chief Executive Officer and Chair of the Board$720K$12.0M$1.1M$13.8M
Patrick Finn, Ph.D.President and Chief Operating Officer$563K$6.7M$711K$8.0M
Adam LaponisChief Financial Officer$490K$3.4M$361K$4.2M
Dennis ChoChief Legal Officer and Corporate Secretary$449K$2.9M$300K$3.6M
Paula GreenSenior Vice President of Human Resources$400K$2.6M$378K$3.3M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Sep 30, 2026

Institutional holders

97 institutions reported Twist Bioscience shares in 13F filings for Sep 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
FMR LLC$1.9B9,695,518+106.2%15.54%
BlackRock, Inc.$1.2B6,386,116+9.5%10.23%
ARK Investment Management LLCCathie Wood$656.6M3,398,057-25.3%5.45%
Vanguard Portfolio Management LLC$603.4M3,122,452+10.5%5.00%
State Street Corp$583.0M3,017,072-6.7%4.83%
Vanguard Capital Management LLC$575.3M2,977,308+10.3%4.77%
Artisan Partners Limited Partnership$395.1M2,044,421-57.4%3.28%
Invesco Ltd.$352.1M1,821,886-5.5%2.92%
Geode Capital Management, LLC$336.2M1,739,376+7.4%2.79%
William Blair Investment Management, LLC$281.0M1,454,117-33.1%2.33%
Morgan Stanley$196.4M1,016,276-14.6%1.63%
JPMorgan Chase & Co.$190.7M1,021,087+397.5%1.64%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings2 managers

Tracked fund managers holding TWST

ManagerValueSharesShare of book
Cathie WoodARK Invest · Q3 2026$656.6M3,398,0573.8%
Farallon CapitalQ2 2026$219.8M2,136,4001.0%

2 of the 97 fund managers we track list TWST shares among the largest positions in their latest 13F. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 416 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Paula GreenSVP of Human ResourcesSold1,007$135.40$136KNov 3, 2026filed Nov 5, 20262d
Robert F. WernerChief Accounting OfficerSold148$135.40$20KNov 3, 2026filed Nov 5, 20262d
Emily M. LeproustChief Executive OfficerSold4,573$135.40$619KNov 3, 2026filed Nov 5, 20262d
Patrick John FinnPresident and COOSold2,565$135.40$347KNov 3, 2026filed Nov 5, 20262d
Dennis ChoSold949$135.40$128KNov 3, 2026filed Nov 5, 20262d
Patrick John FinnPresident and COOSold2,245$134.59$302KOct 23, 2026filed Oct 27, 20262d
Adam LaponisChief Financial OfficerSold2,462$156.30$385KOct 9, 2026filed Oct 13, 20261d
Emily M. LeproustChief Executive OfficerSold · scheduled · 8 lines4,548$202.15$919KOct 5, 2026filed Oct 7, 20262d
Robert F. WernerChief Accounting OfficerSold1,482$188.88$280KOct 2, 2026filed Oct 5, 20261d
Dennis ChoSold9,514$188.88$1.8MOct 2, 2026filed Oct 5, 20261d
Emily M. LeproustChief Executive OfficerSold · scheduled45,736$188.88$8.6MOct 2, 2026filed Oct 5, 20261d
Emily M. LeproustChief Executive OfficerSold · scheduled655$200.00$131KOct 1, 2026filed Oct 5, 20262d
Patrick John FinnPresident and COOSold25,714$188.88$4.9MOct 2, 2026filed Oct 5, 20261d
Paula GreenSVP of Human ResourcesSold10,088$188.88$1.9MOct 2, 2026filed Oct 5, 20261d
Adam LaponisChief Financial OfficerSold8,057$188.88$1.5MOct 2, 2026filed Oct 5, 20261d
Emily M. LeproustChief Executive OfficerSold · scheduled · 3 lines3,594$175.62$631KSep 24, 2026filed Sep 25, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

STOCK Act2 disclosures of 2 on record · median 39d of the 45 allowed

Congress trades in TWST

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Dwight EvansStockSale$1,001 - $15,000+122.1% since the saleEstimated exit price $50.25, close on Wed Mar 30, 2022Current price $111.60, close on Fri Nov 13Mar 30, 2022Apr 25, 202226d
Dwight EvansStockPurchase$1,001 - $15,000+247.0% since the tradeEstimated entry price $32.16, close on Mon Mar 2, 2020Current price $111.60, close on Fri Nov 13Mar 2, 2020Apr 23, 202052d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in TWST filterable by party, chamber, type and account.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 16, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on TWST show and how current they are.

Are insiders buying or selling TWST?

Across the 16 most recent open-market filings shown here, 0 were purchases and 16 were sales. 4 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded TWST?

Dwight Evans disclosed TWST transactions in the filings shown here.

How quickly are TWST trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 39 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track